# About Ipamorelin Safe — independent editorial publisher > Ipamorelin Safe is an independent editorial project that publishes summaries of the peer-reviewed research literature on ipamorelin. Not a clinic, not a pharmacy. For research purposes only. Authored, hand-bound, and deliberately careful — what the published research documents, and what it does not. ## What this publication is Ipamorelin Safe is an independent editorial project that publishes summaries of the peer-reviewed research literature on ipamorelin. The publication is not a clinic. It does not employ clinicians and it does not provide medical advice. It does not manufacture, sell, or distribute any product. Its work is editorial commentary on publicly available science. The word 'safe' in the domain name is editorial framing — the site's subject is safety, the careful authored question of what the literature does and does not document about how the molecule behaves in research settings. It is not a marketing claim that the molecule is safe for any human use. The 1998 selectivity characterization in rats and swine [1], the 1999 single-dose human PK/PD work in eight male volunteers per dose group [2], the 2014 Phase 2 trial in 114 postoperative patients over seven days IV [3], and the FDA's October 2024 review of ipamorelin for inclusion in the 503A Bulks Regulation [5] are the central documents this publication reads. ## Editorial standards Every quantitative claim on this site is sourced to a specific entry in the references list. Dose values, half-life numbers, study sample sizes, adverse event percentages, and regulatory dates all carry a bracketed numeric citation that resolves to a peer-reviewed publication, a ClinicalTrials.gov record, or an FDA briefing document. The publication does not invent research. If a claim is not in the cited literature, it does not appear on the site. The publication does not recommend doses, propose protocols, or describe non-clinical use as if it were clinical practice. Where the literature is silent on a question — and on ipamorelin, the literature is silent on most chronic-exposure questions — that silence is named explicitly rather than papered over with reassurance. The editorial voice is intentionally authored. The design language is that of a hand-bound quarterly. The goal is the careful, paced reading that a peptide with this much marketing noise around it actually deserves. ## What this publication is not Ipamorelin Safe is not a clinic, not a pharmacy, not a telehealth service, and not a vendor. It does not connect readers with clinicians or with suppliers. It does not sell ipamorelin, ipamorelin combinations, reconstitution materials, or any other product. It does not write prescriptions, accept symptoms for triage, or provide a medical opinion on any individual situation. Readers looking for medical advice should consult a licensed clinician in their jurisdiction. Readers looking to purchase ipamorelin in the United States should know that, as of late 2024, there is no FDA-sanctioned compounding pathway for the substance [5][6], and that the gray-market supply channel has documented systematic quality failures [14]. Those facts are part of the published record and are reported on this site for completeness; they are not a recommendation about what to do with them. ## Sourcing methodology Citations on this site are drawn from indexed peer-reviewed journals (European Journal of Endocrinology, Pharmaceutical Research, International Journal of Colorectal Disease, Growth Hormone and IGF Research, British Journal of Pharmacology, Toxicologic Pathology, Endocrine-Related Cancer, JCSM Rapid Communications, Journal of Neurogastroenterology and Motility, Physiology and Behavior, Neuroendocrinology Letters), from ClinicalTrials.gov for registered trial records, from the U.S. Food and Drug Administration's Pharmacy Compounding Advisory Committee materials, and from the World Anti-Doping Agency Prohibited List. Where regulatory documents are referenced through secondary legal or news coverage, the original FDA source is also cited. The aim is that every claim is traceable to a primary or near-primary source that a reader can verify. ## References [1] Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. [2] Gobburu JV et al. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin in Human Volunteers. Pharmaceutical Research. 1999;16(9):1412-1416. [3] Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Phase 2 ipamorelin RCT in postoperative ileus. International Journal of Colorectal Disease. 2014;29(12):1527-1534. [5] U.S. FDA. PCAC Briefing Document (October 29, 2024) — Ipamorelin Acetate / free base review for 503A. 2024. [6] U.S. FDA / Lexology / Holt Law summaries. FDA Briefing Document on Ipamorelin — aggregation, immunogenicity, unnatural amino acids. 2024. [14] Preventive Medicine Daily editorial / pharmacovigilance review. Gray-Market Peptides from China. 2024. --- For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.